Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,768,884 papers from all fields of science
Search
Sign In
Create Free Account
AZD5363
Known as:
Akt inhibitor AZD5363
A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers
J. Robertson
,
R. Coleman
,
+17 authors
J. Gee
2018
Corpus ID: 80558504
Background: AKT is an important intracellular control point through which Type 1 growth factors and IGFR signal. Mutations in…
Expand
Review
2017
Review
2017
Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II…
A. Gonçalves
,
T. Bachelot
,
+17 authors
F. André
2017
Corpus ID: 78779716
Background A genomic-driven therapeutic strategy in metastatic breast cancer (MBC) was recently demonstrated as feasible in the…
Expand
2017
2017
Generation and investigation of resistance mechanisms to AZD5363 in breast cancer
S. Whelan
2017
Corpus ID: 90210944
The PI3K/AKT pathway is a key regulator of proliferation, growth and survival in mammalian cells and aberrations in the…
Expand
2017
2017
AZD5363 inhibits cell proliferation, migration and induces apoptosis of breast cancer MDA-MB-231 cells
Ruo-Tong Li
,
H. Cui
,
Feng-Ze Wang
,
A. Yu
,
Shu-Juan Qin
,
Xuecong Wang
2017
Corpus ID: 80560256
Objective: To investigate the effects of AZD5363, an inhibitor of protein kinase B (Akt), on proliferation, migration and…
Expand
2016
2016
Corrigendum The hVps 34-SGK 3 pathway alleviates sustained PI 3 K / Akt inhibition by stimulating mTORC 1 and tumour growth
R. Bago
,
E. Sommer
,
+7 authors
D. Alessi
2016
Corpus ID: 32736730
We would like to apologise for the oversight in not referring to another recently published study that some of us co-authored…
Expand
2016
2016
AKT3 represses aneuploidy
K. Noguchi
,
Keita Hongama
,
Shiori Hariki
,
Yuma Nonomiya
,
K. Katayama
,
Y. Sugimoto
2016
Corpus ID: 207857919
The suppression of mitotic Aurora kinases (AURKs) by AURK inhibitors frequently causes cytokinetic failure, leading to polyploidy…
Expand
2014
2014
KT inhibition synergistically enhances growth-inhibitory effects f gefitinib and increases apoptosis in non-small cell lung cancer ell lines
Puglisi
,
P. Thavasua
,
+4 authors
U. Banerji
2014
Corpus ID: 52886233
Objectives: EGFR inhibitors are ineffective against most EGFR wild-type non-small cell lung cancer, for which novel treatment…
Expand
2013
2013
Cancer Therapy : Preclinical BlockedAutophagyUsingLysosomotropicAgentsSensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD 5363
F. Lamoureux
,
C. Thomas
,
+5 authors
A. Zoubeidi
2013
Corpus ID: 28159667
Purpose: Prostate cancer development is often associated with deletion or silencing of tumor suppressor phosphatase and tensin…
Expand
2012
2012
Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors
X. Fu
,
Vijetha Kumar
,
+13 authors
R. Schiff
2012
Corpus ID: 70865177
Background: Hyperactive PI3K signaling is associated with a more aggressive subtype of estrogen receptor (ER) positive breast…
Expand
2012
2012
Traitement combiné du cancer
B. Davies
2012
Corpus ID: 193726810
La presente invention concerne une combinaison comprenant AZD5363, ou un sel pharmaceutiquement acceptable de celui-ci, et au…
Expand